The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EU mergers and takeovers (Oct 23)

Wed, 23rd Oct 2013 11:17

BRUSSELS, Oct 23 (Reuters) - The following are mergers underreview by the European Commission and a brief guide to the EUmerger process:

APPROVALS AND WITHDRAWALS

-- U.S. group Koch Industries to acquireelectronic components maker Molex (approved Oct. 23)

NEW LISTINGS

-- Japan's Suntory Beverage & Food Ltd to buyBritish drugmaker GlaxoSmithKline Plc's Lucozade andRibena brands (notified Oct. 22/deadline Nov. 27)

-- U.S. bank Goldman Sachs to acquire sole control ofBritish motor insurer Hastings Insurance Group (notified Oct.21/deadline Nov. 26/simplified)

EXTENSIONS AND OTHER CHANGES

None

FIRST-STAGE REVIEWS BY DEADLINE

OCT 24

-- Private equity firm Triton to buy telecoms and energyinfrastructure builder Alpine Energie from Spanish constructiongroup FCC (notified Sept. 19/deadline Oct.24/simplified)

OCT 25

-- Private equity firm CVC Capital Partners to buy some ofCampbell Soup Co's brands (notified Sept. 20/deadlineOct. 25)

OCT 29

-- Dutch dredger Boskalis and investment companyReggeborgh to acquire joint control of subsea power cablessupplier Visser & Smit Marine Contracting B.V. which is nowsolely controlled by Reggeborgh (notified Sept. 24/deadliineOct. 29)

NOV 4

-- Private investment firm TPG and CaixaBank S.A. to set upa property joint venture by acquiring the business of CaixaBankunit Servihabitat (notified Sept. 27/deadline Nov. 4/simplified)

-- Piper Verlag GmbH to acquire a 50 percent stake in thejoint venture G+J RBA GmbH & Co which is now solely owned byGerman publisher Gruner + Jahr AG & Co (notified Sept.27/deadline Nov. 4/simplified)

NOV 5

-- Switzerland-based INEOS and Belgian chemicals companySolvay to form a joint venture (notified Sept.16/deadline extended to Nov. 5 from Oct. 21 after Solvay offeredconcessions)

-- British telecoms operator Vodafone to buy aminority stake in Vodafone Omnitel N.V. from U.S. peer VerizonCommunications Inc (notified Sept. 30/deadline Nov.5/simplified)

NOV 6

-- South African furniture retailer Steinhoff InternationalHoldings to acquire electrical appliances retailerRudolf Leiner Gesellschaft m.b.H. and LKMBeteiligungsgesellschaft m.b.H. (notified Oct. 1/deadline Nov.6/simplified)

-- Hutchison 3G UK to acquire Telefonica Ireland,a unit of Spanish telecoms provider Telefonica (notified Oct. 1/deadline Nov. 6)

NOV 12

-- U.S. maker of scientific and laboratory equipment ThermoFisher Scientific to buy genetic testing equipment makerLife Technologies (notified Oct. 7/deadline Nov. 12)

NOV 14

-- Japanese trading house Mitsui & Co, IskandarInvestment Berhad (IIB) which is majority owned by Malaysianstate investor Khazanah Nasional Berhad, andinvestment company UWI Capital One to acquire joint control ofMedini Iskandar Malaysia Sdn Bhd, which is now jointlycontrolled by IIB and UWI (notified Oct. 9/deadline Nov.14/simplified)

NOV 18

-- U.S. asset management fund Ares Management LLC andCanada's Ontario Teachers Pension Plan Board to acquire jointcontrol of U.S. building products company CPG International LLC,which is now solely controlled by Ares (notified Oct.11/deadline Nov. 18/simplified)

-- Norwegian telecoms operator Telenor to take astake in a venture owned by Norwegian publishing house Schibsted and Singapore Press Holdings, and also to set up ajoint venture with Schibsted focusing on South American business(notified Oct. 11/deadline Nov. 18/simplified)

-- Parkwind, which is an investment vehicle of Belgiansupermarket chain Colruyt Group, and special purposevehicle Summit Renewable Energy, which is owned by Japan'sSumitomo Corp, to acquire joint control of wind farmoperator Belwind 1, which is now solely owned by SummitRenewable Energy (notified Oct. 11/deadline Nov. 18/simplified)

-- French luxury goods company LVMH to buy an 80percent stake in Italian luxury cashmere clothing brand LoroPiana (notified Oct. 11/deadline Nov. 18/simplified)

NOV 21

-- Czech energy company EPH to acquire Slovakian powerdistributor Stredoslovenska Energetika (SSE) from Frenchstate-controlled utility EDF (notified Oct. 15/deadlineNov. 21)

NOV 25

-- Private equity investor 3i Group to acquire sole controlof ferry operator Scandferries Holdings which is now jointlycontrolled by 3i and ACP Affiliates (notified Oct. 18/deadlineNov. 25/simplified)

MARCH 10

-- Swiss cement maker Holcim to buy some ofMexican peer Cemex's assets in Germany (notified Sept. 3/dateline extended to March 10 from Oct. 22after the Commission opened an in-depth investigation into thedeal)

GUIDE TO EU MERGER PROCESS

DEADLINES:

The European Commission has 25 working days after a deal is filed for a first-stage review. It may extend that by 10 workingdays to 35 working days, to consider either a company's proposedremedies or an EU member state's request to handle the case.

Most mergers win approval but occasionally the Commission opens a detailed second-stage investigation for up to 90 additional working days, which it may extend to 105 working days.

SIMPLIFIED:

Under the simplified procedure, the Commission announces theclearance of uncontroversial first-stage mergers without givingany reason for its decision. Cases may be reclassified asnon-simplified -- that is, ordinary first-stage reviews -- untilthey are approved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.